EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies

Endoplasmic reticulum aminopeptidase 1 (ERAP1) plays a central role in the modulation of the immunopeptidome
in all human cells and in N-terminal trimming of immunopeptides to 9-10mers in the endoplasmic reticulum
(ER) for loading and presentation via major histocompatibility-1 (MHC-1).
Therapeutic inhibition of ERAP1 provides a mechanism to increase the visibility of previously hidden neoantigens and
the visibility of the tumor to the immune system.
Discover how our TrueDiscovery Immunopeptidome Profiling services enabled Grey Wolf to assess immunomodulation following ERAP inhibition.